2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06C.04 Impact of TP53/EGFR Mutations in Advanced-Stage NSCLC: LATAM Population

Pdf Summary

The study titled "Impact of TP53/EGFR Mutations on Advanced-Stage NSCLC: LATAM Population," led by Thanya Runciman, investigates the prognostic implications of concurrent TP53 and EGFR mutations in patients with advanced non-small cell lung cancer (NSCLC) within Latin American (LATAM) populations. Conducted by researchers from Peru and Mexico, the study reviewed 462 patients across two oncological centers from January 2015 to December 2022. After applying exclusion criteria, 90 out of the 104 patients with EGFR mutations were included for analysis.<br /><br />Key findings include:<br /><br />- TP53 mutations were found in 62.9% of the assessed cohort, while the EGFR mutation occurred frequently with deletions at 19 (52.2%) and L858R (21.1%).<br />- The median number of genetic co-mutations per patient was three, with a range of one to twelve.<br />- Treatment was administered to 90% of the patients, leading to an overall response rate (ORR) of 57.8%.<br />- The median overall survival (mOS) stood at 38.5 months across the entire cohort. However, a marked disparity was noted between patients with TP53 mutations (mOS: 28.7 months) and those without (wild-type group mOS: 57.18 months).<br />- For progression-free survival (PFS), the median stood at 14.7 months, with no significant difference observed between mutated (12.8 months) and wild-type groups (17.2 months).<br /><br />The analysis concluded that the presence of both TP53 and EGFR mutations negatively impacts overall survival but not progression-free survival. These results suggest a need for large-scale studies to validate these findings further, given the absence of notable variances depending on the type of EGFR mutation.

Asset Subtitle

Thanya Runciman

Meta Tag

Speaker Thanya Runciman

Topic Pathology and Biomarkers

Keywords

TP53 mutations

EGFR mutations

NSCLC

Latin American population

prognostic implications

overall survival

progression-free survival

genetic co-mutations

oncological centers

large-scale studies